Compare AbbVie Inc (ABBV) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Domino's Pizza, Inc. — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Domino's Pizza, Inc. trades at $357.34 (market cap $11.51B). The key difference: AbbVie Inc is far larger — about 38.1× Domino's Pizza, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | DPZ | |
|---|---|---|
Market Cap | $438.19B | $11.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $467.30 |
52-Week Low | $197.38 | $282.89 |
Enterprise Value | $502.45B | $16.47B |
Dividend Yield | 2.79% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
DPZ trades at $350.95, down 2.09% on the day, with a bullish technical signal supported by moving averages and ADX. The company reported Q2 2026 EPS of $4.07, missing estimates, but revenue growth remains steady, with 2025 revenue at $4.94B and net income of $601.70M. Recent news highlights Domino's beta testing a new website and app with customer incentives, while institutional positions show mixed adjustments.
The outlook is mixed: analyst consensus is a Moderate Buy with a $371.67 price target, implying upside, but near-term risks include weaker ticket trends, margin pressure from rising costs, and consecutive EPS misses. High debt levels and insider selling add caution, though operational cash flow strength and brand initiatives support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
